drugset / Trial / NCT00087477
A Pilot Study of Pivanex in Patients With Malignant Melanoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This pilot study will assess the safety and efficacy of Pivanex alone in patients with malignant melanoma who have relapsed after treatment with chemotherapy or Interleukin-2 (IL-2). Pivanex is an investigational agent.
Timeline
- Start
- 2004-01
- Primary completion
- —
- Completion
- 2004-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pivanex | Small molecule | 2500 mg/m2 | Intravenous |